FDA Details Label Development For Fast-Tracked Drugs
The U.S. Food and Drug Administration on Monday explained how drugmakers should develop labels for products that receive accelerated approval, describing an array of caveats and revisions that are needed at...To view the full article, register now.
Already a subscriber? Click here to view full article